Johnson & Johnson just paused its coronavirus vaccine trials after an
'unexplained illness' in a participant
businessinsider(商業內幕) Lydia Ramsey Pflanzer 25 minutes ago
Johnson & Johnson said Monday that it had temporarily halted its coronavirus
vaccine trials after a participant experienced an unexplained illness, the
second major setback to hit a late-stage test of a coronavirus immunization.
The pharma giant said it paused all further dosing in the trials after a
participant fell ill. The pause in the trial, which is aiming to enroll
60,000 people to determine if the vaccine is safe and effective, was first
reported by Stat News' Matthew Herper.
J&J said the participant's illness is being reviewed by an independent board
as well as by company doctors. The company didn't share more information
about the nature of the illness, citing patient privacy.
"We must respect this participant's privacy," J&J said in a statement. "We're
also learning more about this participant's illness, and it's important to
have all the facts before we share additional information."
A coronavirus vaccine trial from British drugmaker AstraZeneca is facing a
similar setback. In September, AstraZeneca paused the trial after a
participant had a potential adverse reaction. The UK arm of the trial has
resumed, though the US portion of the trial is still paused and being
investigated further by the US Food and Drug Administration.
Other late-stage vaccine trials from Pfizer and Moderna are underway, and
they could yield results this year.
J&J, the world's largest healthcare company, started its late-stage trial in
September to determine whether the shot can prevent COVID-19. The trial is
also designed to provide information about whether the vaccine is safe to
administer to potentially millions of people.
The trial had initially expected to yield early results by the end of 2020.
Depending on how long the trial is paused, the findings could be delayed. J&J
didn't provide any information about the length of the pause.
簡單中譯：
強生(Johnson & Johnson)本來疫苗已經進入最後階段臨床(三大洲，六萬人測試)
但是因為產生無法解釋的疾病，已經緊急終止計畫
https://reurl.cc/2gKWb4
心得/評論：
本來預計可以在領先地位的強生(NYSE: JNJ)，三十分鐘前宣布緊急暫停計畫